Adrenal Androgens Impact on Neurosteroids

  • Marta Caretto
  • Andrea Giannini
  • Tommaso SimonciniEmail author
  • Andrea R. Genazzani
Part of the ISGE Series book series (ISGE)


The steroidogenic endocrine glands and local synthesis both contribute to the pool of steroids present in the central nervous system and peripheral nervous system. The available clinical and experimental findings support the critical role of neurosteroids during fertile life and reproductive aging and their relationship with endogenous and exogenous sex steroids. Protective steroid hormones such as dehydroepiandrosterone (DHEA) and particularly its sulfated derivative, DHEA sulfate (DHEAS), are the most abundant circulating steroid hormones; but the plasma concentrations of DHEA and DHEAS progressively decline with age. Evidence suggests that lower levels of DHEA are associated with cardiovascular, cognitive, and sexual impairment in women. The brain metabolism and the implications of DHEA treatment in postmenopausal women will also be discussed.


Androgens Neurosteroids DHEA Adrenal Brain CNS 


  1. 1.
    Turcu A, Smith JM, Auchus R, Rainey WE. Adrenal androgens and androgen precursors: definition, synthesis, regulation and physiologic actions. Compr Physiol. 2014;4(4):1369–81.CrossRefGoogle Scholar
  2. 2.
    Campbell B. Adrenarche in comparative perspective. Am J Hum Biol. 2011;23:44–52.CrossRefGoogle Scholar
  3. 3.
    Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab. 1992;75(4):1002–4.Google Scholar
  4. 4.
    Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59(3):551–5.CrossRefGoogle Scholar
  5. 5.
    Baulieu EE. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res. 1997;52:1–32.PubMedGoogle Scholar
  6. 6.
    Friess E, Schiffelholz T, Steckler T, Steiger A. Dehydroepiandrosterone – a neurosteroid. Eur J Clin Investig. 2000;30(Suppl 30):46–50.CrossRefGoogle Scholar
  7. 7.
    Moffat SD, Zonderman AB, Harman SM, Blackman MR, Kawas C, Resnick SM. The relationship between longitudinal declines in dehydroepiandrosterone sulfate concentrations and cognitive performance in older men. Arch Intern Med. 2000;160:2193–8.CrossRefGoogle Scholar
  8. 8.
    Sherwin BB. Steroid hormones and cognitive functioning in aging men: a mini-review. J Mol Neurosci. 2003;20(3):385–93.CrossRefGoogle Scholar
  9. 9.
    Stárka L, Dušková M, Hil M. Dehydroepiandrosterone: a neuroactive steroid. J Steroid Biochem Mol Biol. 2015;145:254–60.CrossRefGoogle Scholar
  10. 10.
    Davis SR, Shah SM, McKenzie DP, Kulkarni J, Davison S, Bel RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metabol. 2008;93(3):801–8.CrossRefGoogle Scholar
  11. 11.
    Barnes DE, Cauley JA, Lui LY, Fink HA, McCulloch C, Stone KL, Yaffe K. Women who maintain optimal cognitive function into old age. J Am Geriatr Soc. 2007;55:259–61.CrossRefGoogle Scholar
  12. 12.
    Laumann E, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537–44.CrossRefGoogle Scholar
  13. 13.
    Davis S, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005;294(1):91–6.CrossRefGoogle Scholar
  14. 14.
    Derogatis L, Rust J, Golombok S, et al. Validation of the Profile of Female Sexual Function (PFSF) in surgically and naturally menopausal women. J Sex Marital Ther. 2004;30:25–36.CrossRefGoogle Scholar
  15. 15.
    Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. 2003;24:152–82.CrossRefGoogle Scholar
  16. 16.
    Davis SR, Panjari M, Stanczyk FZ. DHEA replacement for postmenopausal women. J Clin Endocrinol Metab. 2011;96:1642–3.CrossRefGoogle Scholar
  17. 17.
    Genazzani AR, Pluchino N, Begliuomini S, et al. Long-term low-dose oral administration of dehydroepiandrosterone modulates response to adrenocorticotropic hormone in early and late postmenopausal women. Gynecol Endocrinol. 2006;22:627–35.CrossRefGoogle Scholar
  18. 18.
    Pluchino N, Ninni F, Stomati M, et al. One-year therapy with 10 mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas. 2008;59:293–303.CrossRefGoogle Scholar
  19. 19.
    Genazzani AR, Stomati M, Valentino V, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric. 2011;14:661–8.CrossRefGoogle Scholar
  20. 20.
    Pluchino N, Genazzani AR. DHEA replacement for postmenopausal women: have we been looking in the right direction? Climacteric. 2015;18:1–3.Google Scholar
  21. 21.
    Genazzani AR, Komm BS, Pickar JH. Emerging hormonal treatments for menopausal symptoms. Expert Opin Emerg Drugs. 2015;20(1):31–46.CrossRefGoogle Scholar
  22. 22.
    Pluchino N, Santoro A, Casarosa E, Wenger JM, Genazzani AD, Petignat P, Genazzani AR. Advances in neurosteroids: role in clinical practice. Climacteric. 2013;16(Suppl 1):8–17.CrossRefGoogle Scholar

Copyright information

© International Society of Gynecological Endocrinology 2019

Authors and Affiliations

  • Marta Caretto
    • 1
  • Andrea Giannini
    • 1
  • Tommaso Simoncini
    • 1
    Email author
  • Andrea R. Genazzani
    • 1
    • 2
  1. 1.Division of Obstetrics and Gynecology, Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
  2. 2.International School for Gynecological and Reproductive Endocrinology, International Society of Gynecological EndocrinologyLocarnoSwitzerland

Personalised recommendations